Physician profile
David J Phillips
NPI 1497730212
$3,460.09
in general payments reported to CMS, 2019-2025
27 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $454 · 2021: $11.91 · 2022: $394 · 2023: $733 · 2024: $597 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $364.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $221.11 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Intuitive Surgical, INC. | $212.36 | 2020 | |
| Pfizer INC. | $184.18 | 2019-2025 | |
| Astellas Pharma US INC | $179.23 | 2020-2023 | Veozah |
| Lilly USA, LLC | $177.29 | 2019-2024 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $162.16 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $127.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $117.36 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $97.78 | 2019-2023 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $82.71 | 2019-2023 | |
| Nevro Corp. | $45.22 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $40.69 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $40.07 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $33.57 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $33.37 | 2019-2022 | |
| Ibsa Pharma INC. | $29.82 | 2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $20.05 | 2024 | Voquezna |
| Genentech USA, INC. | $19.41 | 2019 | |
| Dexcom, INC. | $18.42 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.19 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $16.20 | 2023 | Rexulti |
| Amarin Pharma, INC. | $14.39 | 2019 | |
| Hikma Pharmaceuticals USA | $13.97 | 2019 | |
| Allergan, INC. | $13.76 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.